Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $767.4 million.

  • Neurocrine Biosciences' Short-term Investments fell 897.88% to $767.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $767.4 million, marking a year-over-year decrease of 897.88%. This contributed to the annual value of $767.4 million for FY2025, which is 897.88% down from last year.
  • Latest data reveals that Neurocrine Biosciences reported Short-term Investments of $767.4 million as of Q4 2025, which was down 897.88% from $774.6 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Short-term Investments peaked at $899.2 million during Q2 2024, and registered a low of $454.8 million during Q3 2021.
  • In the last 4 years, Neurocrine Biosciences' Short-term Investments had a median value of $780.5 million in 2023 and averaged $741.4 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Short-term Investments soared by 1012.86% in 2024, and later plummeted by 2086.3% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Short-term Investments stood at $454.8 million in 2021, then soared by 71.61% to $780.5 million in 2023, then grew by 8.02% to $843.1 million in 2024, then decreased by 8.98% to $767.4 million in 2025.
  • Its Short-term Investments was $767.4 million in Q4 2025, compared to $774.6 million in Q3 2025 and $711.6 million in Q2 2025.